glp 1 agonists and sglt2 inhibitors combination Perspectives in weight control in diabetes – GLP-1–glucagon dual agonism SGLT2 inhibitors vs GLP-1 receptor

metformin may be considered

Michael F Costello, National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life, Melbourne, Victoria, Australia

Tirzepatide (Zepbound, Mounjaro) Tirzepatide is a first-in-class dual agonist

Conclusion GLP-1 RAs provide clinically meaningful weight loss primarily through selective fat mass reduction, with relative preservation of lean tissue, supporting their role in achieving quality weight loss

In this context, cardiologists are required to discuss with insurance companies the prescription of GLP-1 RAs and to advocate their use as cardioprotective gents in the presence of robust body of evidence